[11C]RTI-32 PET studies of the dopamine transporter in early dopa- naive Parkinson's disease: Implications for the symptomatic threshold

Neurology

Volumn 48, Issue 6, 1997, Pages 1578-1583

  Guttman, Mark ^a,b   Burkholder, J ^a   Kish, S J ^a   Hussey, D ^a   Wilson, A ^a   DaSilva, J ^a   Houle, S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; COCAINE DERIVATIVE; DOPAMINE TRANSPORTER; RTI 32; SELEGILINE; TRACER; UNCLASSIFIED DRUG; CARBON; CARRIER PROTEIN; DIAGNOSTIC AGENT; MEMBRANE PROTEIN; NERVE PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NERVE ENDING; NIGRONEOSTRIATAL SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; RATING SCALE; CHEMISTRY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE COURSE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; SCINTISCANNING; SUBSTANTIA NIGRA; TIME;

ADULT; CARBON RADIOISOTOPES; CARRIER PROTEINS; DISEASE PROGRESSION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; SUBSTANTIA NIGRA; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030610740     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.6.1578     Document Type: Article

References (21)

1. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-880.
2. Hornykiewicz O. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. Adv Neurol 1986;60:140-147.
3. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-455.
4. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter is decreased in the caudate nucleus in Parkinson's disease. Synapse 1991;9(1):43-49.
5. Niznik HB, Fogel EF, Fassos EF, Seeman P. The dopamine transporter is absent in Parkinsonian putamen and reduced in the caudate nucleus. J Neurochem 1991;56:192-198.
6. Wilson JM, Levey AI, Rajput A, et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 1996;47:718-726.
7. Brooks DJ. Functional imaging in relation to parkinsonian syndromes. J Neurol Sci 1993;115:1-17.
8. 11C]-carboxymethoxy-3B-aryltropanes: radiotracers for the dopamine transporter. J Labelled Compd Radiopharm 1994;34:759-765.
9. 18F]-labelled cocaine analogues as potential dopamine transporter ligands for positron emission tomography. Nucl Med Biol 1996;23:141-146.
10. Boja JW, Carroll FI, Rahman MA, et al. New, potent cocaine analogs: ligand binding and transport studies in rat striatum. Eur J Pharmacol 1990;184:329-332.
11. Fahn S, Elton R, et al. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden C, Calne D, Goldstein M, eds. Recent developments in Parkinson's disease. Vol 2. Florham Park, NJ: MacMillan Healthcare Information, 1987:153-164.
12. Woods RP, Mazziotta JC, Cherry SR. MRI-PET registration with automated algorithm. J Comput Assist Tomogr 1993;17: 536-546.
13. 11C]WIN 35428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-431.
14. 11C]β-CFT in early Parkinson's disease. Synapse 1995;21:97-103.
15. 123I]β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46:231-237.
16. 11C]-CFT and PET in a primate model of parkinsonism. Neuroreport 1992;3:265-268.
17. 11C]-CFT. Exp Neurol 1994;126:305-309.
18. Ueki A, Chong PN, Albanese A, et al. Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin. Neuropharmacol 1989;28:1089-1097.
19. 18F]dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1995;59:597-600.
20. 18F]fluorodeoxyglucose and positron emission tomography. Neurology 1995;45:1995-2004.
21. Alexander GL, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357-381.